Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "Oncology"

703 News Found

Moderna and Merck announce personalized mRNA cancer vaccine
Diagnostic Center | December 13, 2022

Moderna and Merck announce personalized mRNA cancer vaccine

Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial


Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial
News | December 13, 2022

Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial

The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama


GSK’s new data underscore important responses with momelotinib for myelofibrosis patients
Diagnostic Center | December 12, 2022

GSK’s new data underscore important responses with momelotinib for myelofibrosis patients

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response


Emmes launches Cell and Gene Therapy Center
News | December 09, 2022

Emmes launches Cell and Gene Therapy Center

The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies


Concord Biotech gets SEBI nod for IPO
News | December 07, 2022

Concord Biotech gets SEBI nod for IPO

The IPO is a complete OFS by existing shareholder Helix Investment Holdings


Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
News | December 05, 2022

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer


Jemperli RUBY phase III trial met its primary endpoint
Diagnostic Center | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival


EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
News | December 05, 2022

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints


Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
News | November 30, 2022

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan


Gland Pharma to buy French pharma company Cenexi
News | November 30, 2022

Gland Pharma to buy French pharma company Cenexi

Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group